ASTH Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

928.03M

+39.51%

0.169

-212.5%

919.85M

+48.27%

0.244

+74.57%

961.44M

+46.83%

0.287

+51.26%

Estimates Revision

The market is revising Downward the revenue expectations for Astrana Health, Inc. (ASTH) for FY2025, with the revenue forecasts being adjusted by -1.57% over the past three months. During the same period, the stock price has changed by -8.14%.

Revenue Estimates for FY2025

Revise Downward

-1.57%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-50.85%

In Past 3 Month

Stock Price

Go Down

-8.14%

In Past 3 Month

6 Analyst Rating

Wall Street analysts forecast ASTH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ASTH is 32.67 USD with a low forecast of 26.00 USD and a high forecast of 37.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

4 Buy

2 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

26.00

Averages

32.67

High

37.00

Current: 0.000

Low

26.00

Averages

32.67

High

37.00

Needham

Matthew Shea

initiated

$28

2025-12-12

Reason

Needham

Matthew Shea

Price Target

$28

2025-12-12

initiated

Reason

Needham analyst Matthew Shea initiated coverage of Astrana Health with a Buy rating and $28 price target. The firm believes value-based care "is at an inflection point," with higher reimbursement rates and heightened utilization working their way into benchmarks. Astrana is "leaning into full risk deals at a greater rate than others in our coverage," the analyst tells investors in a research note. Needham believes the shift to risk and organic growth opportunities in core and emerging markets can drive 20%-30% growth for Astrana Health over the long term.

Jefferies

Buy

downgrade

$44 -> $37

2025-11-25

Reason

Jefferies

Price Target

$44 -> $37

2025-11-25

downgrade

Buy

Reason

Jefferies lowered the firm's price target on Astrana Health to $37 from $44 and keeps a Buy rating on the shares. The bar for fiscal 2026 EBITDA is low and implies little confidence in the full-risk contract conversion delays that management is assuming will be effective in the first quarter of 2026, the analyst tells investors in a research note. Jefferies believes potential upside for Astrana from Medicare Advantage in 2026 is underappreciated, but thinks proof-points on 1H26 trends are needed to restore confidence.

Barclays

Andrew Mok

Equal Weight

downgrade

$36 -> $26

2025-11-24

Reason

Barclays

Andrew Mok

Price Target

$36 -> $26

2025-11-24

downgrade

Equal Weight

Reason

Barclays analyst Andrew Mok lowered the firm's price target on Astrana Health to $26 from $36 and keeps an Equal Weight rating on the shares post the Q3 report. The company's contracting trade-off is understandable, but introduces an element of risk to its EBITDA targets in 2026 and 2027, the analyst tells investors in a research note.

TD Cowen

Ryan Langston

Buy

downgrade

$40 -> $35

2025-11-10

Reason

TD Cowen

Ryan Langston

Price Target

$40 -> $35

2025-11-10

downgrade

Buy

Reason

TD Cowen analyst Ryan Langston lowered the firm's price target on Astrana Health to $35 from $40 and keeps a Buy rating on the shares. The firm said its forward estimates reflecttheir cautious outlook on Medicaid and the VBC environment.

BTIG

David Larsen

Buy

downgrade

$70 -> $50

2025-07-30

Reason

BTIG

David Larsen

Price Target

$70 -> $50

2025-07-30

downgrade

Buy

Reason

BTIG analyst David Larsen lowered the firm's price target on Astrana Health to $50 from $70 and keeps a Buy rating on the shares. The company could face headwinds from higher cost trends, though it has already provided favorable comments around Q2 results, the analyst tells investors in a research note. There have been some worries about home-health reimbursement, but the specialty medical trend and home-health and rehab volumes will likely far offset these worries, the firm added.

Barclays

Andrew Mok

Hold

Initiates

$36

2025-04-01

Reason

Barclays

Andrew Mok

Price Target

$36

2025-04-01

Initiates

Hold

Reason

Barclays initiated coverage of Astrana Health with an Equal Weight rating and $36 price target. The company is well positioned to capture improving rates in the government sector, but the scale and complexity of the pending Prospect deal tempers excitement, the analyst tells investors in a research note. The firm believes the near-term execution risks are real given the scale. As such, it comes out on the sidelines.

Valuation Metrics

The current forward P/E ratio for Astrana Health Inc (ASTH.O) is 30.44, compared to its 5-year average forward P/E of 37.33. For a more detailed relative valuation and DCF analysis to assess Astrana Health Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

5Y Average PE

37.33

Current PE

30.44

Overvalued PE

56.59

Undervalued PE

18.07

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

5Y Average EV/EBITDA

11.57

Current EV/EBITDA

6.49

Overvalued EV/EBITDA

17.98

Undervalued EV/EBITDA

5.16

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

1.34

Current PS

0.33

Overvalued PS

2.39

Undervalued PS

0.28

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

ASTH News & Events

Events Timeline

No data

News

1.0

01-06PRnewswire

Astrana Health to Present at 2026 JP Morgan Healthcare Conference, Showcasing AI Innovations

1.0

01-06Newsfilter

Astrana Health to Present at J.P. Morgan 2026 Healthcare Conference, Showcasing AI-Driven Care Solutions

2.0

01-05NASDAQ.COM

ASTH Stock Analysis: 52-Week Low at $20.12 with Current Price at $27.40

People Also Watch

Frequently Asked Questions

What is Astrana Health Inc (ASTH) stock price today?

The current price of ASTH is 27.945 USD — it has decreased -0.97 % in the last trading day.

What is Astrana Health Inc (ASTH)'s business?

Astrana Health, Inc. is a physician-centric, artificial intelligence (AI)-powered healthcare company focused on delivering patient-centered care. The Company provides care coordination services to each major constituent of the healthcare delivery system, including patients, families, primary care physicians, specialists, acute care hospitals, alternative sites of inpatient care, physician groups, and health plans. The Company's segments include Care Partners, Care Delivery, and Care Enablement. Its Care Partners segment is focused on building and managing provider networks by partnering with, empowering, and investing in provider partners aligned on a shared vision for coordinated care delivery. Its Care Delivery organization includes primary care, multi-specialty care, and ancillary care services. Its Care Enablement segment represents a comprehensive platform that integrates clinical, operational, financial, and administrative information. It supports more than 20,000 providers.

What is the price predicton of ASTH Stock?

What is Astrana Health Inc (ASTH)'s revenue for the last quarter?

Astrana Health Inc revenue for the last quarter amounts to 956.05M USD, increased 99.71 % YoY.

What is Astrana Health Inc (ASTH)'s earnings per share (EPS) for the last quarter?

Astrana Health Inc. EPS for the last quarter amounts to 0.01 USD, decreased -96.97 % YoY.

What changes have occurred in the market's expectations for Astrana Health Inc (ASTH)'s fundamentals?

How many employees does Astrana Health Inc (ASTH). have?

Astrana Health Inc (ASTH) has 1900 emplpoyees as of January 09 2026.

What is Astrana Health Inc (ASTH) market cap?

Today ASTH has the market capitalization of 1.41B USD.